Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers-Reference-Cited by-同舟云学术

Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers

Published:2007-05 Issue:5 Volume:18 Page:874-880
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Mazouni C.,Kau S.-W.,Frye D.,Andre F.,Kuerer H.M.,Buchholz T.A.,Symmans W.F.,Anderson K.,Hess K.R.,Gonzalez-Angulo A.M.,Hortobagyi G.N.,Buzdar A.U.,Pusztai L.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/18/5/874/580788/mdm008.pdf

Reference22 articles.

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials;Clarke;Lancet,2005

2. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer;Berry;JAMA,2006

3. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors;Guarneri;J Clin Oncol,2006

4. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27;Bear;J Clin Oncol,2003

5. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual;Singletary;Surg Clin North Am,2003

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of miRNA-200c and βIII tubulin as promising markers for clinical decision making in locally advanced breast cancer patients receiving taxanes therapy;Gene Reports;2023-12

2. Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer;The Breast;2022-12

3. Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years;Breast Cancer Research and Treatment;2022-04-22

4. Evaluation of Complete Pathological Regression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients with BRCA1 Founder Mutation Aided Bayesian A/B Testing Approach;Diagnostics;2021-06-23

5. Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes;Cancers;2020-03-29